cadenas

ITCC-082 LENVATINIB

  • Innovative Therapies
    for Children with Cancer in Europe
  • Contact us

ITCC-082 LENVATINIB

A multicentre, open-label, randomised, Phase 2 study to compare the efficacy and safety of lenvatinib (LEN) in combination with ifosfamide (IFO) and etoposide (ETO) versus IFO and ETO in subjects from 5 years to <18 years (and adults) with relapsed or refractory osteosarcoma who have been treated with 1 prior chemotherapy regimen

Promotor Name : EISAI

Investigator Name : Dr Nathalie GASPAR

Trial registered on clinicaltrial.gov: NCT04154189